Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

Multiple Sclerosis

Volumn 9, Issue 6, 2003, Pages 592-599

  Teitelbaum, Dvora ^a   Brenner, T ^b   Abramsky, O ^b   Aharoni, R ^a   Sela, M ^a   Arnon, R ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Antibodies; Copaxone ; Copolymer I; EAE; Multiple sclerosis; Non neutralizing antibodies; Therapeutic efficacy

Indexed keywords

AMINO ACID COPOLYMER; ANTIBODY; ANTIGEN; CYTOKINE; GLATIRAMER; GLATIRAMER ANTIBODY; HUMAN MONOCLONAL ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MYELIN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[84-102]; PEPTIDE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; RELAPSE; REMISSION; SUPPRESSOR CELL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 0344098868     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms963oa     Document Type: Article

References (35)

1. Lucchinetti C, Buck W, Noseworthy J. Multiple sclerosis: Recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001; 14: 259-69.
2. Halpike JF. Clinical aspects of multiple sclerosis: In Halpike JF, Adams CWM, Tourtellotte WW eds. Multiple Sclerosis. London: Chapman & Hall, 1983: 129-61.
3. Martin R, McFarland H, McFarlin DE. Immunological aspects of demyelinating diseases. Ann Rev Immunol 1992, 10: 153-87.
4. Steinman L. Weisman A, Altman D. Major T-cell responses in multiple sclerosis. Mol Med Today 1995; 1: 79-83.
5. Ben-Nun A, Mendel I, Bakiner R, Fridkis-Hareli M, Teitelbaum D, Arnon R et al. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of Copolymer 1 on MOG-induced disease. J Neurol 1996; 243: S14-S22.
6. Warren KG, Catz I, Johnson E, Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 1944; 35: 280-89.
7. Arnon R. The development of Cop 1 (Copaxone®), an innovative drug for the treatment of multiple sclerosis. Personal reflections. Immunol Letts 1996; 50: 1-15.
8. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacoter 2 2001; 1149-65.
9. Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002; 58: S10-S22.
10. IFNB MS Study Group UBC MS/MRI Analysis group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized combined trial. Neurology 1995; 45: 1277-85.
11. PRISMS Study group. Randomized double-blind placebo controlled study of interferon β-1a relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
12. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971; 1: 242-48.
13. Bornstein MB, Miller A, Slagle S, Weitzmann M, Crystal H, Drexler E et al. A pilot trial of Copolymer 1 in extracerbating-remiting multiple sclerosis. N Engl J Med 1987; 317: 408-14.
14. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
15. Teitelbaum D, Aharoni R, Fridkis-Hareli M, Arnon R, Sela M. Development of Copolymer 1 (Copaxone) as a specific drug against multiple sclerosis. In Shoenfeld Y ed. The Decade of Autoimmunity. Amsterdam, The Netherlands: Elsevier Science, 1999: 191-96.
16. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific TH2 cells accumulate in the central nervous system of mice protected against EAE by Copolymer 1. PNAS 2000; 97: 11472-77.
17. Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 induced by Copolymer 1. J Neuroimmunol 1998; 91: 135-46.
18. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M et al. T cell immunity of Copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000; 97: 7446-51.
19. Ziemssen T, Kümpfel T, Wolfgang E, Klinkert F, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper-1 and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy. Brain 2002; 125: 2381-91.
20. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human encephalitogen. Eur J Immunol 1973; 3: 273-79.
21. Teitelbaum D, Aharoni R, Sela M, Arnon R. Cross-reactions and specificites of monoclonal antibodies against myelin basic protein and against synthetic Copolymer 1. Proc Natl Acad Sci USA 1991; 88: 9528-32.
22. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Rieven-Kreitman R et al. Humoral and cellular immune response to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115: 152-60.
23. Meiner Z, Kott E, Schechter D, Nisipanu P, Korczyn AD, Fletcher S et al. Copolymer 1 in relapsing-remitting multiple sclerosis: A multi-centre trial. In Abramsky O, Ovadia H eds. Frontiers in Multiple Sclerosis: Clinical Research and Therapy. London: Martin Dunitz, 1997: 213-21.
24. Hirshfeld H, Teitelbaum D, Arnon R, Sela M. Basic encephalitogenic protein: A simplified purification on sulphoethylsephadex. FEBS Lett 1970; 7: 317-20.
25. Merrifield RB. Automated synthesis of peptides. Science 1965; 150: 178-85.
26. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic Copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 1992; 89: 137-41.
27. Brenner T, Timore Y, Wirguin I, Abramsky O, Steinitz M. In-vitro synthesis of antibodies to acetylcholine receptor by Epstein-Barr virus-stimulated B-lymphocytes derived from patients with myasthenia gravis. J Neuroimmunol 1989; 24: 217-22.
28. Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ et al. Direct binding of myelin basic protein and synthetic Copolymer 1 to Class II major histocompatibility complex molecules on living antigen-presenting cells - Specificity and promiscuity. Proc Natl Acad Sci 1994; 91: 4872-76.
29. Lando Z, Teitelbaum D, Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. Eur J Immunol 1979; 132: 2156-60.
30. Goodman JW. Modeling determinants for recognition by B cells and T cells in antigen determinants and immune regulation. Chem Immunol 1989; 46: 1-22.
31. Zisman E, Sela M, Ben-Nun A, Mozes E. Dichotomy between the T and B cell epitopes of the synthetic polypeptide (T,G) A - L. Eur J Immunol 1994; 24: 2497-505.
32. Lanzavecchia, A. Receptor-mediated antigen uptake and its effect on antigen presentation to Class II-restricted T lymphocytes. Ann Rev Immunol 1990; 8: 77-893.
33. Schalke BCG, Flinkert WEF, Wekerle H, Dusyer DS. Enhanced activation of a T cell line specific for acetylcholine receptor (AChR) by using anti-AChR monoconal antibodies plus receptors. J Immunol 1985; 34: 3643-48.
34. Ure DR, Rodriguez M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating diseases. FASEB J 2002; 16: 1260-62.
35. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-66.